US Patent 8,758,733 (Bimatoprost 0.03% for Chemotherapy-Related Eyelash Loss): Scope, Claim Coverage, and Landscape
United States Patent 8,758,733 is directed to methods for growing eyelashes in chemotherapy patients by topically applying bimatoprost at 0.03% w/v to eyelids at defined time windows relative to chemotherapy (before, during, or after) and with dosing, duration, and outcome attributes. The claims are structured around (1) a dose-and-timing method and (2) dependent refinements on frequency, duration (6 and 12 months post-chemo), anatomical application sites, and clinical outcome framing (length, thickness, darkness; hypotrichosis treatment; reduced adverse ocular/skin effects).
What do the claims actually cover?
1) Core independent claim scope
The patent includes two substantively independent method claims (independent claim set appears at claim 1 and claim 13):
- Claim 1: “A method of growing eyelashes in chemotherapy patients” by applying 0.03% w/v bimatoprost to eyelids in one of three timing states: before, during, or after chemotherapeutic treatment.
- Claim 13: “A method of treating loss of eyelashes in patients undergoing chemotherapy” using the same 0.03% w/v bimatoprost application and same timing options (before, during, and after).
Coverage anchor: the combination of (a) chemotherapy patient population, (b) bimatoprost at 0.03% w/v, and (c) application to eyelids, with timing relative to chemotherapy. The claims do not require a specific cancer type, chemotherapy regimen, or eyelash loss severity score in the text provided.
2) Dependent claim refinements that narrow coverage
Dependent claims add functional and procedural limits that can materially affect infringement analysis:
-
Post-chemo dosing frequency
- Claim 2: “at least once a day after chemotherapeutic treatment.”
- Claim 8: “twice a day.”
- Claim 14-18: “at least once a day” and “once a day” appear in the claim 13 line.
-
Duration windows after chemotherapy
- Claim 4: “at least 6 months after completing chemotherapeutic treatment.”
- Claim 5: “at least 12 months after completing chemotherapeutic treatment.”
- Claims 16-17 mirror those durations in the claim 13 lineage.
-
Outcome framing (comparative result language)
- Claim 3: results in eyelashes longer/thicker/darker vs eyelashes of chemotherapy patients who did not receive the 0.03% bimatoprost.
- Claim 6: number or length increases compared with post-chemotherapy patients not receiving 0.03% bimatoprost.
- Claims 15 and 20 similarly carry “longer/thicker/darker” and comparative language.
-
Treatment characterization
- Claim 10: “effectively treats post-chemotherapeutic hypotrichosis.”
-
Add-on therapy step
- Claim 11: method further comprising administration of one selected from:
- Minoxidil®
- Propecia® (finasteride)
-
Adverse event reduction compared to idiopathic hypotrichosis use
- Claim 12: “lower incidence” of conjunctival hyperemia, punctate keratitis, erythema of the eyelid, eye pruritus, and skin hyperpigmentation than in patients receiving 0.03% w/v bimatoprost for idiopathic hypotrichosis.
-
Anatomical application location
- Claim 9: applied to upper or lower eyelid margin of each eye.
- Claim 19: applied to the upper eyelid.
- Claim 20: applied to the upper or lower eyelid.
Claim-by-claim scope map (infringement-critical elements)
Claim 1
- Population: “chemotherapy patients”
- Act: applying 0.03% w/v bimatoprost
- Site: “to the eyelids”
- Timing: before, during, or after chemotherapeutic treatment
Claim 2
- Adds: post-chemo frequency at least once a day
Claim 3
- Adds: outcome comparative result (length/thickness/darkness) vs untreated chemotherapy patients
Claim 4
- Adds: post-chemo duration at least 6 months
Claim 5
- Adds: post-chemo duration at least 12 months
Claim 6
- Adds: outcome comparative result (increase in number or length)
Claim 7
- Adds: “bimatoprost is added during and after chemotherapeutic treatment” (timing refinement)
Claim 8
- Adds: frequency twice a day
Claim 9
- Adds: site refinement to upper or lower eyelid margin of each eye
Claim 10
- Adds: efficacy framing as treating post-chemotherapeutic hypotrichosis
Claim 11
- Adds additional systemic/another active step: Minoxidil® or Propecia®
Claim 12
- Adds: safety comparative advantage vs idiopathic hypotrichosis use of the same 0.03% concentration, requiring “lower incidence” of a set of ocular and skin adverse events
Claim 13
- Independent method mirrored from claim 1:
- Population: patients undergoing chemotherapy
- Act: applying 0.03% w/v bimatoprost
- Site: eyelids
- Timing: before/during/after
Claims 14-20
- Add the same categories of limitations:
- Claim 14: at least once a day
- Claim 15: length/thickness/darkness comparative result
- Claim 16: at least 6 months post-chemo
- Claim 17: at least 12 months post-chemo
- Claim 18: once a day
- Claim 19: upper eyelid
- Claim 20: upper or lower eyelid
What is the practical “coverage wedge” and what can be designed around?
Coverage wedge
The patent is narrow on drug identity and concentration:
- It requires bimatoprost and specifically 0.03% w/v.
It is narrow on route/site:
- It requires topical eyelid application (“to the eyelids” and eyelid margin variants).
It is narrow on patient condition:
- It requires chemotherapy-related eyelash loss (before, during, or after chemotherapy).
Most design-around levers
Within the claim language provided, the main infringement-critical levers are:
- Concentration: substituting a different strength than 0.03% w/v removes match to the claimed dose.
- Indication/patient status: using in a non-chemotherapy population avoids the “chemotherapy patients” limitation.
- Timing: claims allow before/during/after, but dependent claims specify “after” and post-chemo duration windows (6 and 12 months). If a regimen never reaches those dependent conditions, those dependent claims are harder to reach.
- Application site: dependent claims specify margin or upper/lower eyelid. The independent claims are broader (“to the eyelids”), so site variation matters more against dependent claims than against claim 1/13.
Patent landscape: how this sits versus established bimatoprost eyelash prior art
Bimatoprost eyelash growth is an established mechanism space
Bimatoprost is a known ocular hypotensive and eyelash-growth active. Market products and earlier disclosures have generally centered on:
- eyelash growth in conditions like idiopathic hypotrichosis,
- the use of topical bimatoprost at low concentration.
This patent’s differentiation is the chemotherapy context, plus claim-specific scaffolding:
- timing relative to chemotherapy,
- post-chemo duration (6 and 12 months),
- comparative safety framed against idiopathic hypotrichosis exposure (claim 12).
Where the landscape pressure comes from
Claim 12 suggests the application distinguishes itself not only on efficacy but also by lower incidence of specific adverse events versus idiopathic hypotrichosis use at the same 0.03% concentration. That creates two landscape pressure points for challengers and entrants:
- they must address novelty/obviousness rooted in already-known bimatoprost eyelash effects, and
- they must deal with whether chemotherapy-specific use is merely an obvious extrapolation from idiopathic hypotrichosis data.
Landscape positioning by claim type
This patent is a method-of-treatment (OTC-style “medical use”) patent, not a formulation patent on bimatoprost composition itself (based on the claim text provided). That means:
- the bimatoprost molecule and concentration are fixed,
- the novelty is concentrated in the patient population and treatment timing/dose regimen.
Scope visualization: what a litigant or freedom-to-operate reviewer would key on
Key claim constraints (hard requirements)
| Element |
Claim language (examples) |
Scope impact |
| Patient condition |
“chemotherapy patients” / “patients undergoing chemotherapy” |
Limits applicability to oncology/chemo status |
| Active |
“bimatoprost” |
Fixes drug identity |
| Strength |
“0.03% w/v” |
Fixes exact concentration |
| Target site |
“apply … to the eyelids” |
Requires eyelid contact |
| Timing |
“before/during/after chemotherapeutic treatment” |
Independent claims cover broad time; dependent claims narrow post-chemo duration/frequency |
Dependent claim “tripwires”
- Post-chemo duration: at least 6 months and 12 months (claims 4-5; 16-17)
- Dosing frequency: at least once daily (claims 2; 14-16) and twice daily (claim 8); once daily (claim 18)
- Anatomy: upper/lower eyelid margin (claim 9) vs upper eyelid (claim 19) vs upper or lower eyelid (claim 20)
- Comparative adverse event reduction: claim 12 requires lower incidence of a defined adverse event set vs idiopathic hypotrichosis patients treated with the same 0.03% bimatoprost concentration
- Combination therapy step: claim 11 adds Minoxidil® or Propecia® administration
Business implications for R&D and investment
1) If you pursue a chemotherapy-eyelash indication
The patent claim set indicates that a competitive program must decide early whether it will:
- align to the claimed 0.03% bimatoprost and chemotherapy timing (high risk of infringement if matching),
- or move to a different concentration, different active, or a different treatment paradigm that does not satisfy “applying 0.03% w/v bimatoprost to eyelids of chemotherapy patients.”
Because the independent claims are broad on “before/during/after,” shifting timing alone is unlikely to clear risk if the patient is still a “chemotherapy patient” and the regimen is eyelid application of 0.03% bimatoprost.
2) If you commercialize within the same dose
A marketer operating in this space faces direct method exposure: the claims are not composition-limited; they are applied-action methods. If the regimen matches any independent claim elements, infringement exposure is anchored.
3) If you plan combination therapy
Claim 11 is a narrow addition but it expands method coverage to include adding Minoxidil® or Propecia®. Product strategies that combine therapies should check whether their full regimen lines up with claim 11’s “further comprising” limitation.
4) Safety and comparative claims
Claim 12 is outcome- and comparison-driven (lower incidence vs idiopathic hypotrichosis treated with 0.03% bimatoprost). While hard comparative clinical endpoints can be contested, the existence of this claim matters for:
- labeling strategies,
- trial design that establishes an evidentiary safety profile for chemotherapy-related eyelash treatment.
Key Takeaways
- US 8,758,733 is a method-of-treatment patent focused on growing eyelashes in chemotherapy patients using topical eyelid application of 0.03% w/v bimatoprost, with timing before/during/after chemotherapy (independent coverage).
- Dependent claims add frequency, post-chemo duration (6 and 12 months), anatomical application (upper/lower eyelid or margin), and comparative efficacy/safety (including a defined adverse-event reduction vs idiopathic hypotrichosis use).
- The most direct design-around levers, based on claim text, are avoiding the exact concentration (0.03% w/v), avoiding treatment in the chemotherapy patient population, and avoiding regimens that satisfy post-chemo dependent duration/frequency and the idiopathic comparison safety framing.
- The landscape risk is concentrated in medical-use method infringement, not in a formulation barrier, because the claims specify drug identity and dose and the act of eyelid application.
FAQs
What is the independent claim’s biggest scope feature?
It permits eyelid application of 0.03% w/v bimatoprost to chemotherapy patients at any of three timing stages: before, during, or after chemotherapy (claims 1 and 13).
Which dependent claims add the tightest treatment-duration constraints?
Claims 4-5 and 16-17 require application for at least 6 months and at least 12 months after completing chemotherapy.
Does the patent require twice-daily dosing?
Only in the dependent claim 8 (twice a day). The independent claims do not require a specific frequency.
Is there a combination therapy step in the claims?
Yes. Claim 11 adds “further comprising” administration of Minoxidil® or Propecia®.
Is there a safety comparison embedded in the claims?
Yes. Claim 12 requires “lower incidence” of several ocular and skin adverse events versus patients receiving 0.03% w/v bimatoprost for idiopathic hypotrichosis.
References
[1] US Patent No. 8,758,733. “Method for growing eyelashes in chemotherapy patients using bimatoprost.” Claims as provided in the prompt.
